UCPMP 2024 Quiz

Brand names from other companies can only be used with prior consent to avoid legal issues and maintain fairness​​.

Endorsements must be based on scientific evidence, and any conflicts of interest must be disclosed to maintain transparency and trust.

Investigating and communicating discrepancies transparently ensures accurate and reliable information is provided to healthcare professionals and patients.

Comparative studies must include head-to-head comparisons with the leading competitor to ensure unbiased and accurate results.

Collaborating with independent organizations and publishing results transparently ensures the integrity and credibility of the research.

Medical representatives must not use inducements or subterfuge to gain access but should schedule appointments​​.

Informational and educational items provided must not exceed Rs. 1000 in value to maintain ethical standards​​.

Informational items should be updated as necessary to ensure they provide accurate and current information​​.

RWE must be presented transparently, including both benefits and limitations, to ensure a balanced and accurate representation of the drug.

Mailings should not carry advertising content that might be seen by the general public to avoid misleading or inappropriate promotion​​.

Withdrawing the drug temporarily ensures patient safety and allows for investigation and appropriate measures to be taken.

Pharmaceutical companies are responsible for ensuring their medical representatives comply with the UCPMP Code​​.

Comparisons must be factual and capable of substantiation to ensure they are fair and accurate​​.

Promotional material must not resemble editorial content to avoid misleading the reader​​.

Promotion of off-label uses requires a detailed explanation of the scientific basis to ensure transparency and accuracy.

Pharmaceutical associations are responsible for constituting an Ethics Committee for monitoring and implementation of UCPMP​​.

No company should offer more than twelve sample packs per drug to any healthcare practitioner per year to control distribution​​.

Patient support programs should focus on providing non-drug related educational support and be independently validated to avoid being perceived as promotional.

Mailings and advertisements must not disguise their real nature to avoid misleading the recipients​​.

Companies must refuse such requests and report them to maintain ethical standards and comply with UCPMP 2024.